Anika Therapeutics, Inc.
About Anika Therapeutics, Inc.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $112.8M
- Net income
- -$10.9M
- Total assets
- $190.3M
- Market cap
- $192.7M
- Gross margin
- 56.6%
- Operating margin
- -9.8%
- Net margin
- -9.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $112.8M
- Cost of revenue
- $49.0M
- Gross profit
- $63.8M
- Operating expenses
- $74.9M
- Operating income
- -$11.1M
- Income tax
- $672.0K
- Net income
- -$10.9M
- EPS (basic)
- $-0.76
- EPS (diluted)
- $-0.76
Balance sheet
- Total assets
- $190.3M
- Current assets
- $103.4M
- Total liabilities
- $46.8M
- Current liabilities
- $21.9M
- Shareholders’ equity
- $143.5M
Cash flow
- Operating cash flow
- $11.2M
- Investing cash flow
- -$401.0K
- Financing cash flow
- -$10.6M
- Net cash flow
- $236.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $192.7M
- EPS (diluted)
- $-0.76
- Shares outstanding
- 13.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 3, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.9M in FY2025.
- Revenue declined 24% from FY2021 to FY2025.
- Gross margin of 56.6%, net margin -9.6%.
- Trading 9% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Anika Therapeutics, Inc..
Write a review
News about Anika Therapeutics, Inc.
News & sentiment via Polygon.io
